Fate Therapeutics (FATE) EBITDA Margin (QoQ) (2012 - 2026)
Fate Therapeutics (FATE) EBITDA Margin (QoQ) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -418.00 |
| Dec 31, 2025 | -54,111.00 |
| Sep 30, 2025 | -5,658.00 |
| Jun 30, 2025 | 59,553.00 |
| Mar 31, 2025 | 78,571.00 |
| Dec 31, 2024 | -161,591.00 |
| Sep 30, 2024 | -103,814.00 |
| Jun 30, 2024 | 198,716.00 |
| Mar 31, 2024 | 21,555.00 |
| Dec 31, 2023 | -23,063.00 |
| Sep 30, 2023 | 406,798.00 |
| Jun 30, 2023 | -665,731.00 |
| Mar 31, 2023 | 9,675.00 |
| Dec 31, 2022 | 43,144.00 |
| Sep 30, 2022 | -12,862.00 |
| Jun 30, 2022 | -4,365.00 |
| Mar 31, 2022 | 208.00 |
| Dec 31, 2021 | -2,249.00 |
| Sep 30, 2021 | -3,521.00 |
| Jun 30, 2021 | 6,595.00 |